Bernard Escudier

Institut Gustave Roussy

Papers

4

Total Citations

3,050

H-Index

3

About

Bernard Escudier is a world-renowned oncologist whose work has fundamentally shaped the management of renal cell carcinoma (RCC). His primary research focus lies in the development of targeted therapies and the establishment of evidence-based clinical guidelines for kidney cancer. As the lead author of the ESMO Clinical Practice Guidelines for RCC, his contributions have become the global standard for diagnosis, treatment, and follow-up, with his 2014 edition alone amassing over 2,200 citations. These guidelines have directly influenced clinical decision-making worldwide, ensuring patients receive optimal, standardized care. Beyond guideline development, Escudier has been a pioneer in investigating novel therapeutic strategies, such as the use of axitinib to downstage tumors and enable nephron-sparing surgery, as seen in the AXIPAN trial. His work bridges the gap between cutting-edge research and practical patient care, making him a pivotal figure in oncology. With a citation impact exceeding 3,000 for his most influential works, Escudier’s legacy is defined by his relentless pursuit of improving outcomes for patients with renal cancer.

Research Focus

Key Achievements

3
H-Index
4
Papers
3,050
Total Citations
763
Avg Citations/Paper
🏆 Most Cited Paper
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2,259 citations · 2014
📈 Most Prolific Year: 2016 (2 Papers)
🤝 Key Collaborators: 24
🏛 Institutions: Institut Gustave Roussy

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago